AbbVie Inc (ABBV) - Total Assets
Based on the latest financial reports, AbbVie Inc (ABBV) holds total assets worth $133.96 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ABBV total equity for net asset value and shareholders' equity analysis.
AbbVie Inc - Total Assets Trend (2010–2025)
This chart illustrates how AbbVie Inc's total assets have evolved over time, based on quarterly financial data.
AbbVie Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
AbbVie Inc's total assets of $133.96 Billion consist of 21.7% current assets and 78.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.9% |
| Accounts Receivable | $12.59 Billion | 9.4% |
| Inventory | $4.95 Billion | 3.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $52.64 Billion | 39.3% |
| Goodwill | $35.64 Billion | 26.6% |
Asset Composition Trend (2010–2025)
This chart illustrates how AbbVie Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is AbbVie Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AbbVie Inc's current assets represent 21.7% of total assets in 2025, a decrease from 38.9% in 2010.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2025, up from 0.1% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 65.0% of total assets, an increase from 46.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 39.3% of total assets.
AbbVie Inc Competitors by Total Assets
Key competitors of AbbVie Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.07 Billion |
|
Novartis AG
MX:NVSN
|
Mexico | MX$110.95 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $115.57 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$208.73 Billion |
|
Virbac SA
PA:VIRP
|
France | €1.82 Billion |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
China | CN¥13.11 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$1.83 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$112.48 Billion |
AbbVie Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.67 | 0.66 | 0.83 |
| Quick Ratio | 0.56 | 0.55 | 0.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-14.23 Billion | $-13.17 Billion | $-5.38 Billion |
AbbVie Inc - Advanced Valuation Insights
This section examines the relationship between AbbVie Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 50.46 |
| Latest Market Cap to Assets Ratio | 2.73 |
| Asset Growth Rate (YoY) | -0.9% |
| Total Assets | $133.96 Billion |
| Market Capitalization | $365.30 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values AbbVie Inc's assets at a significant premium (2.73x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: AbbVie Inc's assets decreased by 0.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for AbbVie Inc (2010–2025)
The table below shows the annual total assets of AbbVie Inc from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $133.96 Billion | -0.89% |
| 2024-12-31 | $135.16 Billion | +0.33% |
| 2023-12-31 | $134.71 Billion | -2.95% |
| 2022-12-31 | $138.81 Billion | -5.27% |
| 2021-12-31 | $146.53 Billion | -2.68% |
| 2020-12-31 | $150.56 Billion | +68.96% |
| 2019-12-31 | $89.11 Billion | +50.15% |
| 2018-12-31 | $59.35 Billion | -16.15% |
| 2017-12-31 | $70.79 Billion | +7.09% |
| 2016-12-31 | $66.10 Billion | +24.60% |
| 2015-12-31 | $53.05 Billion | +92.82% |
| 2014-12-31 | $27.51 Billion | -5.77% |
| 2013-12-31 | $29.20 Billion | +8.11% |
| 2012-12-31 | $27.01 Billion | +38.35% |
| 2011-12-31 | $19.52 Billion | -7.64% |
| 2010-12-31 | $21.13 Billion | -- |
About AbbVie Inc
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various c… Read more